44.200.137.63
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

FDA Alerts

FDA approved selpercatinib for RET fusion+ advanced solid tumors

The U.S. Food and Drug Administration has approved selpercatinib (Retevmo; Eli Lilly) 40 mg & 80 mg capsules for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-